2N Pharma Aps

Development in activities and financesThe profit for the period 1 January 2022 to 31 December 2022 amounted to DKK 0.270m.


The profit is mainly related to capitalised drug development costs and related tax incentives. Management considers the result satisfactory and in accordance with expectations.

Capital resources
During the reporting period, the company has continued its development of therapeutic drugs for the treatment of ALS and Parkinson’s disease. During the period, the company incurred DKK 3.467m development costs that have been capitalised, as well as costs for research and other activities not capitalised. The company received an equity contribution of DKK 1.9m from the parent company, 2N Pharma Holding ApS and the balance sheet as of 31 December 2022 shows equity of DKK 11.048M.

As a development company without significant sources of revenue, the company is depending on investments and grants to fund its operations. The board and management team continues discussions with a range of Danish and international investment funds and pharmaceutical companies. However, the investment climate was challenging during 2022 and it has taken longer than anticipated to raise significant equity funding. However, the 2N Pharma team remains optimistic and committed, and expect improved investor sentiment during 2023.

Key research activities during 2023 and 2024 will be funded by a grant of USD 0.944m, approximately DKK 6.5m from the United States Department of Defense and a grant of DKK 0.9m from the Danish Innovation Fund awarded in March 2023.